You are here

Fadi S. Braiteh

Fadi S. Braiteh is a medical oncologist and clinical researcher at Comprehensive Cancer Centers of Nevada (CCCN) where he has served as a principal investigator for more than 200 cancer clinical trials. Since 2010, Dr. Braiteh has been the Director of the Translational Oncology Program (TOP)-Phase I and Director of Gastro-Intestinal Malignancies Program at CCCN where he leads a team in the development of novel anti-cancer agents. Additionally, he is a Clinical Associate Professor a the University of Nevada School of Medicine in Nevada. He is a board certified in internal medicine, palliative medicine and medical oncology with expertise in gastro-intestinal and thoracic oncology.

Dr. Braiteh served as a member or board member of numerous national and state associations such American Society of Clinical Oncology committees, the National Cancer Institute (NCI) Pancreatic Cancer Task Force, and the Nevada Oncology Society Task Force. He is a member of the lecturing faculty with numerous professional societies including American Society of Clinical Oncology, American Medical Association, Academy of Clinical Research Professionals, and Academy of Pharmaceutical Physicians and Investigators.

Dr. Braiteh earned his medical degree in 1998 from Saint Joseph University in Beirut, Lebanon. In 2003, he completed his internal medicine internship and residency at the Hospital of Saint Raphael, Yale School of Medicine in New Haven, Connecticut. From 2003-2009, Dr. Braiteh completed three fellowships – medical oncology, phase I drug development and palliative care and symptom management – at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, while he earned PhD credits for a program in molecular biology and human investigation.

Prior to joining CCCN in 2010, Dr. Braiteh worked as a medical oncologist and Director of the Phase I Program and Drug Development Center at the Cancer and Hematology Centers of Western Michigan in Grand Rapids, Michigan. During this time, he was a Clinical Assistant Professor of Medicine at the School of Human Medicine at Michigan State University, and scientific investigator for the Program of Translational Medicine and Phase I Clinical Trials at Van Andel Research Institute in Grand Rapids, Michigan.

Dr. Braiteh has published more than 100 peer-reviewed articles, abstracts and book chapters in various publications including Nature, Lancet, Lancet Oncology, Journal of Clinical Oncology (JCO) , Clinical Cancer Research and The Oncologist. He recently published articles in Nature on cancer immunotherapy for Atezolizumab (Anti-PDL1 antibody) and in The Lancet Oncology on novel treatments in lung and pancreatic cancers. Dr. Braiteh is frequently invited to attend conferences around the country to lecture to his peers about clinical research and novel cancer treatments. He dedicates significant time to lobby for high-quality patient care including symptoms relief and palliative medicine. In addition to numerous media outlets in Las Vegas, Dr. Braiteh has been featured nationally in The New York Times in relation to his work with gene mutations.